Related Experiment Video
Updated: Jul 9, 2026
Single Cell Measurement of Dopamine Release with Simultaneous Voltage-clamp and Amperometry
Published on: November 21, 2012
Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons
Gary A Gudelsky1, Bryan K Yamamoto
1University of Cincinnati, James L. Winkle College of Pharmacy, 3225 Eden Ave., Cincinnati, OH 45267, United States. Gary.Gudelsky@uc.edu
Abstract:
3,4-Methylenedioxymethamphetamine (MDMA) is an amphetamine derivative and a popular drug of abuse that exhibits mild hallucinogenic and rewarding properties and engenders feelings of connectedness and openness. The unique psychopharmacological profile of this drug of abuse most likely is derived from the property of MDMA to promote the release of dopamine and serotonin (5-HT) in multiple brain regions. The present review highlights primarily data from studies employing in vivo microdialysis that detail the actions of MDMA on the release of these neurotransmitters. Data from in vivo microdialysis experiments indicate that MDMA, like most amphetamine derivatives, increases the release of dopamine in the striatum, n. accumbens and prefrontal cortex. However, the release of dopamine evoked by MDMA in each of these brain regions appears to be modulated by concomitantly released 5-HT and the subsequent activation of 5-HT2A/C or 5-HT2B/C receptors. In addition to its stimulatory effect on the release of monoamines, MDMA also enhances the release of acetylcholine in the striatum, hippocampus and prefrontal cortex, and this cholinergic response appears to be secondary to the activation of histaminergic, dopaminergic and/or serotonergic receptors. Beyond the acute stimulatory effect of MDMA on neurotransmitter release, MDMA also increases the extracellular concentration of energy substrates, e.g., glucose and lactate in the brain. In contrast to the acute stimulatory actions of MDMA on the release of monoamines and acetylcholine, the repeated administration of high doses of MDMA is thought to result in a selective neurotoxicity to 5-HT axon terminals in the rat. Additional studies are reviewed that focus on the alterations in neurotransmitter responses to pharmacological and physiological stimuli that accompany MDMA-induced 5-HT neurotoxicity.
Insights
3,4-Methylenedioxymethamphetamine (MDMA) promotes dopamine and serotonin release, influencing brain activity and behavior. High doses may cause neurotoxicity, affecting serotonin axon terminals.
Area of Science:
- Neuroscience
- Psychopharmacology
- Neurochemistry
Background:
- 3,4-Methylenedioxymethamphetamine (MDMA) is an amphetamine derivative known for its psychoactive effects, including mild hallucinogenic and rewarding properties.
- Its unique effects are linked to the modulation of neurotransmitter release, particularly dopamine and serotonin (5-HT), in various brain regions.
Purpose of the Study:
- To review and detail the actions of MDMA on neurotransmitter release, primarily using in vivo microdialysis data.
- To explore the mechanisms underlying MDMA's effects on dopamine, serotonin, and acetylcholine release.
- To examine the consequences of MDMA administration, including energy substrate changes and potential neurotoxicity.
Main Methods:
- In vivo microdialysis was employed to measure neurotransmitter release in specific brain regions.
- Studies reviewed focused on the acute and repeated administration of MDMA.
- Analysis included neurotransmitter responses to pharmacological and physiological stimuli in the context of MDMA-induced neurotoxicity.
Main Results:
- MDMA significantly increases dopamine release in the striatum, nucleus accumbens, and prefrontal cortex.
- Serotonin (5-HT) release and subsequent 5-HT2A/C or 5-HT2B/C receptor activation modulate dopamine release evoked by MDMA.
- MDMA also enhances acetylcholine release in the striatum, hippocampus, and prefrontal cortex, secondary to other receptor activations.
- MDMA increases extracellular glucose and lactate concentrations in the brain.
- Repeated high-dose MDMA administration in rats leads to selective neurotoxicity of 5-HT axon terminals.
Conclusions:
- MDMA acutely enhances the release of dopamine, serotonin, and acetylcholine in the brain through complex receptor interactions.
- While acutely stimulating, repeated high-dose MDMA exhibits neurotoxic effects on serotonin terminals, altering neurotransmitter system function.
- Understanding these neurochemical actions is crucial for comprehending MDMA's effects and potential long-term consequences.
Related Concept Videos
01:29Drugs Affecting Neurotransmitter Synthesis
01:22CNS Stimulants: Psychedelic Agents
01:21Drugs Affecting Neurotransmitter Release or Uptake
01:25Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:24CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
01:23Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...